(Reuters) -Abbott Laboratories fell short of first-quarter revenue estimates on Tuesday, suggesting that the medical device maker may be facing slowing sales of its COVID-19 test kits as vaccinations gain steam. In the quarter, COVID-19...
READ MORE
J&J reports $100 million in vaccine sales as results top forecasts
(Reuters) -Johnson & Johnson beat expectations for quarterly earnings and raised its dividend payouts to shareholders on Tuesday, while reporting $100 million in sales of its COVID-19 vaccine, whose use was paused by U.S. regulators...
READ MORE
Abbott’s results a litmus test for COVID-19 testing demand
By Manojna Maddipatla (Reuters) – Investors will be squarely focused on Abbott Laboratories results on Tuesday to assess the impact of swift vaccination rollout on demand for the company’s COVID-19 tests. Diagnostic test...
READ MORE
Pandemic prompts European life sciences real estate rush
By Carolyn Cohn LONDON (Reuters) – London’s Francis Crick Institute was already a magnet for investors in the capital’s so-called Knowledge Quarter, but the coronavirus pandemic has lifted interest in offices and...
READ MORE
Australia-New Zealand travel bubble launches with lopsided demand
By Jamie Freed SYDNEY (Reuters) – A testing and quarantine free travel bubble between Australia and New Zealand launched with lopsided demand, according to airlines and data firms, with an unusually high number of the travellers...
READ MORE
J&J, other drugmakers go to trial in California in $50 billion case over ‘deadly legacy’ of opioids
By Nate Raymond and Brendan Pierson (Reuters) -Four drugmakers helped cause the deadly U.S. opioid epidemic by deceptively marketing their drugs and downplaying their addictive risks, a lawyer for several California counties argued on...
READ MORE